A comprehensive examination of ACE-2 receptor and prediction of spike glycoprotein and ACE-2 interaction based on in silico analysis of ACE-2 receptor
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
ACE-2 receptor plays a vital role not only in the SARS-CoV-induced epidemic but also in some diseases. Studies have been carried out on the interactions of ACE-2-SARS-CoV proteins. However, comprehensive research has not been conducted on ACE2 protein by using bioinformatic tools. The present study especially two places, G104 and L108 points, which are effective in protecting the structure of the ACE-2 protein, play a critical role in the biological functioning of this protein, and play an essential role in determining the chemicalphysical properties of this protein, and play a crucial role for ACE-2 protein-SARS CoV surface glycoprotein, were determined. It was also found that the G104 and L108 regions were more prone to possible mutations or deletions than the other ACE-2 protein regions. Moreover, it was determined that all possible mutations or deletions in these regions affect the chemical-physical properties, biological functions, and structure of the ACE-2 protein. Having a negative GRAVY value, one transmembrane helix, a significant molecular weight, a long-estimated half-life as well as most having unstable are results of G104 and L108 points mutations or deletions. Finally, it was determined that LQQNGSSVLS, which belong to the ACE-2 protein, may play an active role in binding the spike protein of SARS-CoV. All possible docking score results were estimated. It is thought that this study will bring a different perspective to ACE-2 _SARS-CoV interaction and other diseases in which ACE-2 plays an important role and will also be an essential resource for studies on ACE-2 protein.
Article activity feed
-
SciScore for 10.1101/2021.12.14.472331: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources ACE□2 isolate, and it’s variant protein: NCBI (National Center for Biotechnology Information) (https://www.ncbi.nlm.nih.gov) was used to obtain the whole sequence of ACE-2 protein (Accession number: NP_068576.1 and sequenced in January 2021), and Molecular Evolutionary Genetic Analysis(MEGA) was used to alignment(Kumar et al.,2016) https://www.ncbi.nlm.nih.govsuggested: (GENSAT at NCBI - Gene Expression Nervous System Atlas, RRID:SCR_003923)Predicting possible change, and its effect on the biological function of the ACE-2 protein: PROVEAN (Protein Variation Effect Analyzer) was used to … SciScore for 10.1101/2021.12.14.472331: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources ACE□2 isolate, and it’s variant protein: NCBI (National Center for Biotechnology Information) (https://www.ncbi.nlm.nih.gov) was used to obtain the whole sequence of ACE-2 protein (Accession number: NP_068576.1 and sequenced in January 2021), and Molecular Evolutionary Genetic Analysis(MEGA) was used to alignment(Kumar et al.,2016) https://www.ncbi.nlm.nih.govsuggested: (GENSAT at NCBI - Gene Expression Nervous System Atlas, RRID:SCR_003923)Predicting possible change, and its effect on the biological function of the ACE-2 protein: PROVEAN (Protein Variation Effect Analyzer) was used to predict whether an amino acid substitution or indel impacts the biological function of a protein(Choi et al.,2012). PROVEANsuggested: (PROVEAN, RRID:SCR_002182)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
